WO2007076318A3 - Camphor-derived cxcr3 antagonists - Google Patents

Camphor-derived cxcr3 antagonists Download PDF

Info

Publication number
WO2007076318A3
WO2007076318A3 PCT/US2006/062222 US2006062222W WO2007076318A3 WO 2007076318 A3 WO2007076318 A3 WO 2007076318A3 US 2006062222 W US2006062222 W US 2006062222W WO 2007076318 A3 WO2007076318 A3 WO 2007076318A3
Authority
WO
WIPO (PCT)
Prior art keywords
camphor
derived
cxcr3 antagonists
cxcr3
antagonists
Prior art date
Application number
PCT/US2006/062222
Other languages
French (fr)
Other versions
WO2007076318A2 (en
Inventor
Jakob Busch-Petersen
Jian Jin
Todd L Graybill
Terence J Kiesow
Ralph A Rivero
Feng Wang
Yonghui Wang
Original Assignee
Smithkline Beecham Corp
Jakob Busch-Petersen
Jian Jin
Todd L Graybill
Terence J Kiesow
Ralph A Rivero
Feng Wang
Yonghui Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Jakob Busch-Petersen, Jian Jin, Todd L Graybill, Terence J Kiesow, Ralph A Rivero, Feng Wang, Yonghui Wang filed Critical Smithkline Beecham Corp
Publication of WO2007076318A2 publication Critical patent/WO2007076318A2/en
Publication of WO2007076318A3 publication Critical patent/WO2007076318A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The instant invention related to camphor derivatives of which are useful in treating diseases wherein inhibition of the exzyme CXCR3 results in beneficial therapy in a mammal.
PCT/US2006/062222 2005-12-21 2006-12-18 Camphor-derived cxcr3 antagonists WO2007076318A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75273205P 2005-12-21 2005-12-21
US60/752,732 2005-12-21

Publications (2)

Publication Number Publication Date
WO2007076318A2 WO2007076318A2 (en) 2007-07-05
WO2007076318A3 true WO2007076318A3 (en) 2007-12-27

Family

ID=38218786

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/062222 WO2007076318A2 (en) 2005-12-21 2006-12-18 Camphor-derived cxcr3 antagonists

Country Status (1)

Country Link
WO (1) WO2007076318A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2776047A4 (en) 2011-11-07 2015-07-22 Gen Hospital Corp Treatment of red blood cells
EA027595B1 (en) 2012-02-02 2017-08-31 Актелион Фармасьютиклз Лтд. 4-(benzoimidazol-2-yl)thiazole compounds and related aza derivatives
SG11201600504TA (en) 2013-07-22 2016-02-26 Actelion Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
AR099789A1 (en) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd DERIVATIVES OF 8- (PIPERAZIN-1-IL) -1,2,3,4-TETRAHYDRO-ISOQUINOLINE
CN107250133B (en) 2015-01-15 2020-09-15 爱杜西亚药品有限公司 Hydroxyalkyl piperazine derivatives as CXCR3 receptor modulators
AR103399A1 (en) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd DERIVATIVES OF (R) -2-METHYL-PIPERAZINE AS CXCR3 RECEIVER MODULATORS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107420A1 (en) * 2002-05-23 2005-05-19 Boehringe Ingelheim Pharma Gmbh & Co. Kg Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases
US20050171092A1 (en) * 2000-04-08 2005-08-04 Astrazeneca Ab, A Sweden Corporation Chemical compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171092A1 (en) * 2000-04-08 2005-08-04 Astrazeneca Ab, A Sweden Corporation Chemical compounds
US20050107420A1 (en) * 2002-05-23 2005-05-19 Boehringe Ingelheim Pharma Gmbh & Co. Kg Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases

Also Published As

Publication number Publication date
WO2007076318A2 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
MX2009006704A (en) New compounds.
ATE542823T1 (en) 4,5-DIHYDRO-Ä1,2,4ÜTRIAZOLOÄ4,3-FÜPTERIDINE AS A PLK1 PROTEIN KINASE INHIBITOR FOR THE TREATMENT OF PROLIFERATIVE DISEASES
WO2007121188A3 (en) Compositions and methods of using r(+) pramipexole
IL186749A0 (en) Dihydrothienopyrimidines for the treatment of inflammatory diseases
AP2010005508A0 (en) Triazole derivatives useful for the treatment of diseases.
WO2007115620A3 (en) Novel cyclobutyl compounds as kinase inhibitors
EP2125855A4 (en) Methods and compositions for the treatment of cancer or other diseases
HK1144390A1 (en) Compositions for the treatment of neoplastic diseases
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
IL196202A0 (en) Indazole derivatives for the treatment of hsp90-induced diseases
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
IL200091A (en) Chitosans for the treatment of nail inflammatory diseases
IL192415A0 (en) Pharmaceutical composition for the treatment of nail diseases
WO2009124962A3 (en) Sulfonamides
IL201562A0 (en) Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
WO2007076318A3 (en) Camphor-derived cxcr3 antagonists
GB0523961D0 (en) The treatment of ophthalmic diseases
ZA201000959B (en) The use of extracts or materials extracted from Piper cubeba L. as an effective component in a drug for the treatment of cancer diseases
WO2010077310A3 (en) Amide derivatives of ethacrynic acid
WO2011076946A3 (en) Methods and compositions for the treatment of alzheimer
WO2008009426A9 (en) 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases
PL1904060T3 (en) Use of phthalocyanine derivates for the non-photodynamic treatment of diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06848449

Country of ref document: EP

Kind code of ref document: A2